INT-787 / Intercept  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INT-787 / Intercept
2022-001639-10: The purpose of this trial is to assess dose related safety, early efficacy, pharmacokinetics and pharmacodynamics of INT-787 in patients with severe alcohol-associated hepatitis (sAH).

Not yet recruiting
2
50
Europe
INT-787, INT-787, Capsule
Intercept Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc.
Severe Alcohol-Associated Hepatitis, Liver disease, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
FRESH, NCT05639543: FXR Effect on Severe Alcohol-Associated Hepatitis () Study

Recruiting
2
50
Europe, US
INT-787, Placebo
Intercept Pharmaceuticals
Alcohol Associated Hepatitis
12/24
12/24

Download Options